Impact of Long-Acting Injectable Antipsychotics (LAI-AP) on the outcome of Young Adults with a First Episode Psychosis (YAFEP)

Poster A55, Thursday, October 20, 11:30 am - 1:00 pm, Le Baron

Amal Abdel-Baki1, Sofia Medrano1, Stéphane Potvin2; 1Centre hospitalier Université Montréal, 2Institut universitaire en santé mentale de Montréal

Purpose: Inadequate adherence to prescribed AP is frequent among Young Adults with a First Episode Psychosis (YAFEP) and it negatively affects the long-term outcome of the illness. Different randomized studies have demonstrate the superiority of LAI-AP vs oral antipsychotics (OAP) in reducing relapses and hospitalization rates. However, participants in these types of studies represent only the minority of patients who may benefit from LAI-AP. Few naturalistic studies are available so we sought to describe the usage profile of LAI-AP and their impact on the outcome of YAFEP in a naturalistic setting. Methods: A 3 year longitudinal study on 430 YAFEP took place in two Early Intervention Services (EIS) within the University of Montreal’s network of early psychosis intervention programs in defined urban catchment areas of Montréal, Québec, Canada. The study compared the characteristics as well as clinical and functional outcome of YAFEP who have received LAI-AP to those who only received OAP. Results: 41% received LAI-AP. This group had a lower premorbid functioning and has sociodemographic and clinical characteristics associated with a less favourable prognosis. Despite a more severe symptomatology, lower functioning and poor prognostic factors upon admission in the LAI-AP group, clinical (CGI, GAF) and functional (QLS, SOFAS, occupational status, etc.) improvements were observed in both groups. Conclusion: These preliminary results suggest that YAFEP with poor prognostic factors seem to benefit from LAI-AP..

Topic Area: First Episode Psychosis

Back to Poster Schedule